For the Inventor, By the Inventor

Enter assignee name

Abivax

USPTO Granted Patents = 38

CIPO Patents = 5

EPO Patents = 23

Trademarks = 1

Forward Citations = 146

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Didier Scherrer (34 out of 34 patents)

Jamal Tazi (32 out of 38 patents)

Romain Najman (30 out of 30 patents)

4. Florence Mahuteau (22 out of 22 patents)

5. Aude Garcel (11 out of 11 patents)

6. Julien Santo (8 out of 8 patents)

7. Pierre Roux (8 out of 17 patents)

8. Noelie Campos (7 out of 7 patents)

9. Gilles Gadea (6 out of 10 patents)

10. Carsten Brock (6 out of 6 patents)

11. Nathalie Cahuzac (6 out of 6 patents)

12. Cécile Apolit (5 out of 5 patents)

13. Philippe Pouletty (4 out of 8 patents)

14. Florence Mahuteau-Betzer (4 out of 9 patents)

15. Florence Mahuteau-betzer (4 out of 4 patents)

38 patents: Sort by Forward Citations

1. 12479802 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2025-11-25),

2. 12421206 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-09-23),

3. 12247018 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-03-11),

4. 12202804 - In vitro or ex vivo methods for screening a quinoline derivative (2025-01-21),

5. 12084422 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2024-09-10),

6. 11992499 - Quinoline derivatives for use in the treatment of inflammation diseases (2024-05-28),

7. 11826372 - Combinations including ABX196 for the treatment of cancer (2023-11-28),

8. 11739073 - Aryl-n-aryl derivatives for treating a RNA virus infection (2023-08-29),

9. 11649211 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

10. 11649210 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

11. 11441181 - miRNA-124 as a biomarker (2022-09-13),

12. 11427566 - Compounds useful for treating cancer (2022-08-30),

13. 11278552 - Combinations including ABX196 for the treatment of cancer (2022-03-22),

14. 11266667 - ABX196 for use in the treatment of bladder cancer (2022-03-08),

15. 11014918 - Compounds and pharmaceutical compositions containing at least one of the compounds (2021-05-25),

Abivax is a biotechnology company that specializes in developing and commercializing innovative therapies for patients with viral infections and inflammatory diseases. Their mission is to improve the lives of patients by leveraging their expertise in immunology to develop novel treatments. Abivax focuses on the discovery and development of antiviral and anti-inflammatory drugs that can target a wide range of diseases, including HIV, hepatitis B, cancer, and autoimmune disorders. Through their research and development efforts, Abivax aims to transform patient care and make a positive impact on global public health.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

38 Patents

#137 in Paris

#587 in France

#17,314 in the World

Abivax

Forward Citations = 146

26 inventors:

Didier Scherrer (34 out of 34 patents)

Jamal Tazi (32 out of 38 patents)

Romain Najman (30 out of 30 patents)

4. Florence Mahuteau (22 out of 22 patents)

5. Aude Garcel (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…